BIODESIX INC Cash Flow Statement
BDSX|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$23M
FY2025
Free Cash Flow
-$24M
FY2025
Capital Expenditures
$259,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
BIODESIX INC used $23M in operating cash flow and negative free cash flow of $24M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.69 (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M | -$65.4M |
| Depreciation & Amortization | $5.7M | $5.8M | $3.3M | $3.6M | $3.2M | $2.9M |
| Operating Cash Flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M | -$21.4M |
| Capital Expenditures | $259.0K | $3.2M | $22.9M | $3.3M | $2.2M | $1.9M |
| Free Cash Flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M | -$23.3M |
| FCF Margin | -26.6% | -72.7% | -93.3% | -126.3% | -55.9% | -51.2% |